Can-Fite announced that Drug Design, Development and Therapy has published an article titled, “Targeting the A3 Adenosine Receptor to Treat Cytokine Release Syndrome in Cancer Immunotherapy.” The article presents data from numerous studies that show adenosine’s role in inhibiting inflammatory cytokine production. Can-Fite’s Piclidenoson, a Phase III drug candidate, and Namodenson, a Phase II drug candidate, both target the A3 adenosine receptor, which the Company believes may treat cytokine release syndrome while also promoting an anti-cancer effect. CRS is a potentially life threatening side effect of cancer immunotherapies including CAR-T. The market for CAR-T drugs is estimated to reach approximately $5.4B in 2024 according to Evaluate Pharma. Can Fite’s platform technology selectively targets A3AR, which plays a central role in mediating the mechanism of inflammation by reducing elevated levels of pro-inflammatory cytokines such as IL-6, IL-1beta, NF-Kbeta, TNF-alpha, and more.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.